Cargando…
Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway
BACKGROUND AND AIMS: Naringenin is an anti-inflammatory flavonoid that has been studied in chronic liver disease. The mechanism specific to its antifibrosis activity needs further investigation This study was to focused on the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) pa...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647116/ https://www.ncbi.nlm.nih.gov/pubmed/36406329 http://dx.doi.org/10.14218/JCTH.2022.00120 |
_version_ | 1784827315608354816 |
---|---|
author | Chen, Li Xia, Siwei Wang, Shuqi Zhou, Yuanyuan Wang, Feixia Li, Zhanghao Li, Yang Kong, Desong Zhang, Zili Shao, Jiangjuan Xu, Xuefen Zhang, Feng Zheng, Shizhong |
author_facet | Chen, Li Xia, Siwei Wang, Shuqi Zhou, Yuanyuan Wang, Feixia Li, Zhanghao Li, Yang Kong, Desong Zhang, Zili Shao, Jiangjuan Xu, Xuefen Zhang, Feng Zheng, Shizhong |
author_sort | Chen, Li |
collection | PubMed |
description | BACKGROUND AND AIMS: Naringenin is an anti-inflammatory flavonoid that has been studied in chronic liver disease. The mechanism specific to its antifibrosis activity needs further investigation This study was to focused on the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) pathway in hepatic stellate cells and clarified the antifibrosis mechanism of naringenin. METHODS: The relationship between the cGAS-stimulator of interferon genes (STING) pathway and liver fibrosis was analyzed using the Gene Expression Omnibus database. Histopathology, immunohistochemistry, fluorescence staining, Western blotting and polymerase chain reaction were performed to assess gene and protein expression levels associated with the cGAS pathway in clinical liver tissue samples and mouse livers. Molecular docking was performed to evaluate the relationship between naringenin and cGAS, and western blotting was performed to study the expression of inflammatory factors downstream of cGAS in vitro. RESULTS: Clinical database analyses showed that the cGAS-STING pathway is involved in the occurrence of chronic liver disease. Naringenin ameliorated liver injury and liver fibrosis, decreased collagen deposition and cGAS expression, and inhibited inflammation in carbon tetrachloride (CCl(4))-treated mice. Molecular docking found that cGAS may be a direct target of naringenin. Consistent with the in vivo results, we verified the inhibitory effect of naringenin on activated hepatic stellate cells (HSCs). By using the cGAS-specific agonist double-stranded (ds)DNA, we showed that naringenin attenuated the activation of cGAS and its inflammatory factors affected by dsDNA. We verified that naringenin inhibited the cGAS-STING pathway, thereby reducing the secretion of inflammatory factors by HSCs to ameliorate liver fibrosis. CONCLUSIONS: Interrupting the cGAS-STING pathway helped reverse the fibrosis process. Naringenin has potential as an antihepatic fibrosis drug. |
format | Online Article Text |
id | pubmed-9647116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | XIA & HE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96471162022-11-18 Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway Chen, Li Xia, Siwei Wang, Shuqi Zhou, Yuanyuan Wang, Feixia Li, Zhanghao Li, Yang Kong, Desong Zhang, Zili Shao, Jiangjuan Xu, Xuefen Zhang, Feng Zheng, Shizhong J Clin Transl Hepatol Original Article BACKGROUND AND AIMS: Naringenin is an anti-inflammatory flavonoid that has been studied in chronic liver disease. The mechanism specific to its antifibrosis activity needs further investigation This study was to focused on the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) pathway in hepatic stellate cells and clarified the antifibrosis mechanism of naringenin. METHODS: The relationship between the cGAS-stimulator of interferon genes (STING) pathway and liver fibrosis was analyzed using the Gene Expression Omnibus database. Histopathology, immunohistochemistry, fluorescence staining, Western blotting and polymerase chain reaction were performed to assess gene and protein expression levels associated with the cGAS pathway in clinical liver tissue samples and mouse livers. Molecular docking was performed to evaluate the relationship between naringenin and cGAS, and western blotting was performed to study the expression of inflammatory factors downstream of cGAS in vitro. RESULTS: Clinical database analyses showed that the cGAS-STING pathway is involved in the occurrence of chronic liver disease. Naringenin ameliorated liver injury and liver fibrosis, decreased collagen deposition and cGAS expression, and inhibited inflammation in carbon tetrachloride (CCl(4))-treated mice. Molecular docking found that cGAS may be a direct target of naringenin. Consistent with the in vivo results, we verified the inhibitory effect of naringenin on activated hepatic stellate cells (HSCs). By using the cGAS-specific agonist double-stranded (ds)DNA, we showed that naringenin attenuated the activation of cGAS and its inflammatory factors affected by dsDNA. We verified that naringenin inhibited the cGAS-STING pathway, thereby reducing the secretion of inflammatory factors by HSCs to ameliorate liver fibrosis. CONCLUSIONS: Interrupting the cGAS-STING pathway helped reverse the fibrosis process. Naringenin has potential as an antihepatic fibrosis drug. XIA & HE Publishing Inc. 2023-02-28 2022-04-28 /pmc/articles/PMC9647116/ /pubmed/36406329 http://dx.doi.org/10.14218/JCTH.2022.00120 Text en © 2023 Authors. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Chen, Li Xia, Siwei Wang, Shuqi Zhou, Yuanyuan Wang, Feixia Li, Zhanghao Li, Yang Kong, Desong Zhang, Zili Shao, Jiangjuan Xu, Xuefen Zhang, Feng Zheng, Shizhong Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway |
title | Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway |
title_full | Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway |
title_fullStr | Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway |
title_full_unstemmed | Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway |
title_short | Naringenin is a Potential Immunomodulator for Inhibiting Liver Fibrosis by Inhibiting the cGAS-STING Pathway |
title_sort | naringenin is a potential immunomodulator for inhibiting liver fibrosis by inhibiting the cgas-sting pathway |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647116/ https://www.ncbi.nlm.nih.gov/pubmed/36406329 http://dx.doi.org/10.14218/JCTH.2022.00120 |
work_keys_str_mv | AT chenli naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT xiasiwei naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT wangshuqi naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT zhouyuanyuan naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT wangfeixia naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT lizhanghao naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT liyang naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT kongdesong naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT zhangzili naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT shaojiangjuan naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT xuxuefen naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT zhangfeng naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway AT zhengshizhong naringeninisapotentialimmunomodulatorforinhibitingliverfibrosisbyinhibitingthecgasstingpathway |